ZovaBio

Zova Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) for the treatment of cancer. The company leverages its proprietary site-specific conjugation platform and novel linker-payload technologies to create highly stable and potent therapeutic candidates. Its lead program, ZV0201, is a HER2-targeting ADC currently in Phase 1 clinical development for patients with advanced HER2-positive solid tumors. ZovaBio's pipeline also includes several preclinical assets targeting TROP2 and Claudin 18.2, aimed at addressing significant unmet needs in oncology. By optimizing the therapeutic index of ADCs, the company seeks to provide more effective and safer treatment options for cancer patients globally.